Varubi
(Rolapitant)Phase 2Small molecule
Varubi is one of 51 small molecule programs targeting Malignant Glioma. It is currently in Phase 2.
1
Indications
8
Total Trials
0
Active Trials
50
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
8
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
199 competitors in Malignant Glioma
#DrugCompanyPhaseTrials
1Bicnu
MMelissa K Accordino
Phase 3
Ceenu
AAzurity Pharmaceuticals
Phase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Thalomid
Bristol-Myers SquibbPhase 2
Camptosar
PfizerPhase 2
Avastin
BBio-Thera Solutions
Phase 2
Sutent
PfizerPhase 2
Leukine
SanofiPhase 2
Zofran
NovartisPhase 2
Imjudo
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chemotherapy4 trials
Show 1 more trial
Intravenous1 trial
Single Dose1 trial
Single Ascending Dose1 trial
Malignant Glioma1 trial
Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
Completed·—·Phase 2·NCT02991456·48 enrolled
Regulatory
FDA Approval Timeline[4]
Sep 1, 2015
VARUBI
NDA NDA206500
Oct 25, 2017
VARUBI
NDA NDA208399
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rolapitant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Varubi. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTerSera Therapeutics LLC